For the Inventor, By the Inventor

Enter assignee name

Conaris Research Institute Ag

USPTO Granted Patents = 13

CIPO Patents = 19

EPO Patents = 11

Forward Citations = 50

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Dirk Seegert (10 out of 10 patents)

Georg Wätzig (7 out of 7 patents)

Stefan Rose-John (4 out of 12 patents)

4. Nikolaus Rahaus (3 out of 3 patents)

5. Georg Waetzig (2 out of 2 patents)

6. Stefan Schreiber (2 out of 3 patents)

7. Georg H Watzig (2 out of 2 patents)

8. Alfred Chi Yeh Liang (1 out of 2 patents)

9. Venkataramana Dingari (1 out of 2 patents)

10. Bent Højgaard (1 out of 1 patent)

11. Jørgen Wittendorff (1 out of 1 patent)

12. Joachim Grötzinger (1 out of 3 patents)

13. Jürgen Scheller (1 out of 2 patents)

14. Stephanie Tenhumberg (1 out of 1 patent)

15. Jessica Daecke (1 out of 1 patent)

13 patents: Sort by Forward Citations

1. 11622938 - Oral pharmaceutical compositions of nicotinamide (2023-04-11),

2. 10888555 - Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota (2021-01-12),

3. 10758552 - Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation (2020-09-01),

4. 10456389 - Extended release nicotinamide formulation (2019-10-29),

5. 10426765 - Pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota (2019-10-01),

6. 9573989 - Sgp130/Fc dimers (2017-02-21),

7. 9034817 - sgp130/Fc dimers for treatment of inflammatory disease (2015-05-19),

8. 8895012 - sgp130/Fc dimers (2014-11-25),

9. 8501696 - Soluble GP130 muteins with improved binding activity (2013-08-06),

10. 8206948 - Optimized nucleotide sequences encoding sgp130 (2012-06-26),

11. 7851182 - Soluble GP130 molecule variants useful as a medicament (2010-12-14),

12. 7629147 - PEGylated soluble GP130-dimers useful as a medicament (2009-12-08),

13. 7534862 - PEGylated soluble gp130-dimers useful as a medicament (2009-05-19),

Conaris Research Institute Ag is a Swiss pharmaceutical company focusing on drug discovery and development in the field of infectious diseases. With a team of experienced researchers and state-of-the-art facilities, Conaris is dedicated to finding innovative solutions to combat global health threats.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 2 2025

13 Patents

#10 in Kiel

#3,060 in Germany

#43,583 in the World

Conaris Research Institute Ag

Forward Citations = 50

27 inventors:

Dirk Seegert (10 out of 10 patents)

Georg Wätzig (7 out of 7 patents)

Stefan Rose-John (4 out of 12 patents)

4. Nikolaus Rahaus (3 out of 3 patents)

5. Georg Waetzig (2 out of 2 patents)

Please report any incorrect information to support@idiyas.com

Loading…